Episode Details

Back to Episodes
Awakn Life Sciences Corp. (AWKN: NEO) Clinic Roll-Out Addresses The Multi-Billion Dollar Addiction Treatment Industry With Psychedelics

Awakn Life Sciences Corp. (AWKN: NEO) Clinic Roll-Out Addresses The Multi-Billion Dollar Addiction Treatment Industry With Psychedelics

Season 3 Episode 164 Published 5 years, 1 month ago
Description

To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.

Awakn has a dual strategic focus:

  1. Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
  2. Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally.

Notable Highlights include:

Sit back, relax and watch this powerful interview with CEO Anthony Tennyson.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us